FailedDiscontinued

Eftilagimod alfa (efti) + Keytruda

Non-small cell lung carcinoma (1L NSCLC)

IMMPImmutep

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: Eftilagimod alfa (efti) + Keytruda
Development stage: Failed
Event type: Discontinued
Indication: Non-small cell lung carcinoma (1L NSCLC)

Research summary

What is being tracked?

This catalyst tracks a Failed discontinued for Eftilagimod alfa (efti) + Keytruda in Non-small cell lung carcinoma (1L NSCLC) . The expected timing is based on the latest available company guidance and may change.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

FailedDiscontinued

Eftilagimod alfa (efti) + Keytruda

Non-small cell lung carcinoma (1L NSCLC)

IMMPImmutep

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: Eftilagimod alfa (efti) + Keytruda
Development stage: Failed
Event type: Discontinued
Indication: Non-small cell lung carcinoma (1L NSCLC)

Research summary

What is being tracked?

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Eftilagimod alfa (efti) + Keytruda

Event details

What is being tracked?

Primary source

Related pipeline programs

Eftilagimod Alpha + Pembrolizumab

IMP761 (LAG-3 agonist)

Eftilagimod alfa (efti) + Keytruda

Event details

What is being tracked?

Primary source

Related pipeline programs

Eftilagimod Alpha + Pembrolizumab

IMP761 (LAG-3 agonist)